[ad_1]
Multinational biotechnology firm Biogen has confirmed it should shut down Biogen Digital Health, a worldwide unit of the biotech firm, and pull out of a examine with Apple. Nonetheless, the corporate says it should proceed to combine some digital capabilities into different features of its enterprise.
“As our CEO Chris Viehbacher talked about when he announced Fit for Growth, a part of the initiative is eradicating layers within the group, turning into much less complicated and extra agile, and making strategic investments in inside and exterior innovation. Because of this, some features are evolving their working fashions,” a Biogen spokesperson informed MobiHealthNews in an electronic mail.
Biogen Digital Well being launched in 2021, and it employs round 150 individuals in Boston, Zurich and Paris. The corporate focuses on merging biology and know-how to enhance neurology, immunology and psychological well being care.
The biotech large stated digital drugs and well being applied sciences will stay a vital a part of its plan to de-risk and speed up its analysis and growth engine and its business operations.
“Biogen Digital Well being is evolving. We’re at the moment assessing our digital technique and potential future investments within the house, and we shall be integrating sure digital capabilities from BDH into related features. We’ll proceed to advance quite a few efforts, comparable to growth of digital biomarkers for Parkinson’s and early AD [Alzheimer’s disease], in addition to our digital options for uncommon ailments. Going ahead, we are going to leverage exterior capabilities and partnerships to seize advances within the subject which are carefully linked to our evolving R&D and business priorities and areas of focus,” the spokesperson stated.
In 2021, the corporate started a study with Apple to research iPhone and Apple Watch sensor knowledge and metrics to distinguish people with regular cognition from these with delicate cognitive impairment to create a cognitive wellness rating that follows shifts in cognitive efficiency over time.
“Concerning the Instinct examine with Apple, although it has been discontinued as a result of Biogen’s R&D prioritization efforts, due to the higher-than-expected degree of engagement of members, the examine stays properly positioned to handle its major aims. Preliminary outcomes help the feasibility, acceptability and functionality to achieve underserved and underrepresented populations and to reliably measure cognition and habits in real-world unsupervised settings. Extra insights from the Examine shall be printed at a later time,” Biogen informed MobiHealthNews.
THE LARGER TREND
Biogen announced it completed its acquisition of California-based pharma firm Reata earlier this week for a reported $7.3 billion. The acquisition provides SKYCLARYS to the corporate’s uncommon illness portfolio, the one FDA-approved remedy for Friedreich’s ataxia within the U.S.
[ad_2]
